Table 5 Cox Proportional Hazard Analysis (Univariate) for Disease free survival.
Characteristics | Hazard Ratio | Lower CI | Upper CI | p-value |
|---|---|---|---|---|
Breast surgery | ||||
Mastectomy | 1 | — | — | — |
BCS | 0.762 | 0.593 | 0.98 | 0.034 |
pT size in cm | ||||
> 5.1 cm | 1 | — | — | — |
<2 cm | 0.476 | 0.326 | 0.695 | <0.001 |
2.1-3 cm | 0.537 | 0.384 | 0.75 | <0.001 |
3.1-5 cm | 0.778 | 0.558 | 1.085 | 0.139 |
Tumour grade | ||||
3 | 1 | — | — | — |
1 | 0.265 | 0.154 | 0.456 | <0.001 |
2 | 0.739 | 0.608 | 0.897 | 0.002 |
Lymphatic invasion | ||||
Yes | 1 | — | — | — |
No | 0.651 | 0.534 | 0.794 | <0.001 |
Lymph nodes | ||||
Positive | 1 | — | — | — |
Negative | 0.501 | 0.413 | 0.608 | <0.001 |
Receptor subgroups | ||||
ER/PR Any/ HER2 + | 1 | — | — | — |
ER/PR +/ HER2− | 0.515 | 0.409 | 0.649 | <0.001 |
Triple Negative | 0.756 | 0.583 | 0.98 | 0.034 |
Adjuvant chemotherapy drugs | ||||
Others | 1 | — | — | — |
Anthracycline based | 0.582 | 0.362 | 0.934 | 0.025 |
Anthracycline-taxane based | 0.758 | 0.488 | 1.176 | 0.216 |
Taxane based | 0.727 | 0.428 | 1.236 | 0.239 |
No chemotherapy | 0.924 | 0.583 | 1.466 | 0.737 |
Endocrine therapy in hormone receptor positive | ||||
Aromatase inhibitors | 1 | — | — | — |
Tamoxifen | 0.954 | 0.701 | 1.298 | 0.765 |
Tamoxifen switched to Aromatase inhibitors | 0.538 | 0.261 | 1.109 | 0.093 |
